Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bullous drug reactions].

M S Hertl-Yazdi1, M Hertl

  • 1Klinik für Dermatologie und Allergologie, Zentrum für Hautkrankheiten, Philipps-Universität Marburg.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|December 31, 2004
PubMed
Summary

Bullous drug exanthems are severe skin reactions occurring 5-14 days after starting medication. Diagnosis involves skin and in vitro tests, with avoidance of the causative drug and glucocorticoids as primary treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Lichen planus pemphigoides after COVID-19 infection.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Concidence of cotrimoxazole induced toxic epidermal necrolysis and chronic Q Fever in an Afghan shepherd.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Context:

  • Bullous drug exanthems are severe cutaneous and mucosal hypersensitivity reactions.
  • These reactions typically manifest 5-14 days post-drug initiation.
  • Current management focuses on drug avoidance and systemic glucocorticoids.

Purpose:

  • To outline the pathogenesis, diagnosis, and management of bullous drug exanthems.
  • To highlight the role of cytotoxic CD8(+) T lymphocytes in drug hypersensitivity.
  • To review diagnostic modalities including skin and in vitro tests.

Summary:

  • Bullous drug exanthems involve cytotoxic CD8(+) T lymphocytes recognizing drug metabolites.
  • Metabolites can form spontaneously (e.g., penicillins) or via cytochrome P450 enzymes (e.g., sulfonamides).
  • Diagnostic tools include prick tests, patch tests (even on prior lesions), and in vitro assays like lymphocyte transformation tests (LTT).

Impact:

  • Improved understanding of drug hypersensitivity mechanisms.
  • Enhanced diagnostic strategies for bullous drug exanthems.
  • Informed clinical decisions regarding drug avoidance and treatment protocols.

Related Experiment Videos